THE STATE OF THE ART OF KEFIR APPLICATIONS AS ADJUNCTIVE THERAPY IN CENTRAL NERVOUS SYSTEM DISEASES
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
The central nervous system (CNS) is affected by several neurodegenerative, psychiatric, and neuroinflammatory disorders, for which conventional therapies still present limitations related to efficacy, safety, and cost. In this context, kefir has been investigated as a potential adjunctive therapy due to its ability to modulate the gut–brain axis. This study aimed to review the state of the art of kefir applications in CNS diseases, focusing on its bioactive compounds, mechanisms of action, and preclinical and clinical evidence. This narrative review was based on searches in major scientific databases, including studies published over the last 15 years. Kefir has a complex microbial composition consisting of lactic acid bacteria, acetic acid bacteria, and yeasts capable of producing kefiran, bioactive peptides, organic acids, free amino acids, and short-chain fatty acids. The available evidence indicates effects on intestinal and blood–brain barrier integrity, inflammatory modulation, tryptophan metabolism, neurotransmitter production, and oxidative stress reduction. Promising findings were observed particularly in depression, epilepsy, and Alzheimer’s disease. However, methodological limitations and the scarcity of robust clinical trials still prevent definitive conclusions regarding its clinical application.
Fields of Study & Subjects
Probiotics and Fermented Foods
Gut microbiota and health
Protein Hydrolysis and Bioactive Peptides
Publication details
- Journal / source
- International Journal of Health Management Review
- Volume
- 12
- Issue
- 1
- Pages
- e468–e468
- Publication date
- 27 March 2026
- Language
- EN